ORASIS PHARMACEUTICALS ANNOUNCES AUSTRALIA SUBMISSION OF A NEW DRUG APPLICATION FOR BESKA FOR THE TREATMENT OF PRESBYOPIA

NDA FilingBeskaQLOSIPositive

AI Analysis

Summary

Orasis Pharmaceuticals announced submission of a New Drug Application for Beska (known as QLOSI in the U.S.) in Australia through Aspen Pharmacare Australia, marking the company's first regulatory submission outside the United States for the presbyopia treatment.

Outcome Details

New Drug Application submitted in Australia

Importance:5/10

Sentiment:

0.50

regulatory_submissioninternational_expansionpresbyopiafirst_ex_us_submission

Related Companies

$TRAX

Read the original article

Published by PR Newswire Pharma on July 15, 2026 1:15 PM

Read Original